Please cite this article in press Sofy Sunny et al., Cardiovascular Diseases: Traditional And Non-Traditional Risk Factors, Indo Am. J. P. Sci, 2024; 11 (01).

1. Celermajer DS, Chow CK, Marijon E, Anstey NM, Woo KS. Cardiovascular disease in the developing world: prevalences, patterns and the potential of early disease detection. J Am Coll. Cardiol. 2012; 60(14):1207-1216.
2. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9(12 Suppl):16-23.
3. Cannon CP. Cardiovascular disease and modifiable cardiometabolic risk factors. Clin Cornerstone 2007; 8(3):11-28.
4. Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framing-ham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet 2014; 383(9921):999-1008.
5. Braunwald E. Shattuck lecture-cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med. 1997; 337(19):1360-1369.
6. Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol. 1995; 76(9):69C-77C.
7. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347(20):1557-1565.
8. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, Ellis SG, LincoffAM, Topol EJ. Prevalence of conventional risk factors in patients with coronary heart dis-ease. JAMA. 2003; 290(7):898-904.
9. Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer AR, Garside DB, Wilson PW. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA. 2003; 290(7):891-897.
10. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care.1993; 16(2):434-444.
11. Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation. 1999; 100(4):354-360.
12. van den Hoogen PCW, Feskens EJ, Nagelkerke NJ, Menotti A, Nissinen A, Kromhout D. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N Engl J Med. 2000; 342(1):1-8.
13. Rodgers A, MacMahon S. Blood pressure and the global burden of cardiovascular disease. Clin Exp Hypertens. 1999; 21(5-6): 543-552.
14. Wingard DL, Barrett-Connor E. Heart disease and diabetes. In: Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, and Bennett PH, eds. Diabetes in America, 2nd edition. Bethesda, MD: U.S. Department of Health and Human Services, pp. 429-448, 1995.
15. Bierman EL. George Lyman DuffMemorial Lecture. Atherogenesis in diabetes. Arterioscler Thromb. 1992; 12(6):647-656.
16. Herlitz J, Karlson BW, Edrardsson N, Emanuelsson H, Hjalmarson A. Prognosis in diabetics with chest pain or other symptoms suggestive of acute myocardial infarction. Cardiology. 1992; 80(3-4):237-245.
17. Miettinen H, Lehto S, Salomaa V, Mahonen M, Niemela M, Haffner SM, Pyorala K, Tuomilehto J. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care. 1998; 21(1):69-75.
18. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-986.
19. Durrington. P. Dyslipidaemia. Lancet 2003; 362(9385):717-731.
20. Prospective Studies Collaboration, Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007; 370(9602):1829-1839.
21. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart dis-ease: overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med. 1992; 152(1):56-64.
22. Verschuren WM, Jacobs DR, Bloemberg BP, Kromhout D, Menotti A, Aravanis C, Blackburn H, Buzina R, Dontas AS, Fidanza F, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures: Twenty- five-year follow-up of the seven countries study. JAMA. 1995; 274(2):131-136.
23. Stamler J, Wentworth D, Neaton JD. Is relationship be-tween serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986; 256(20):2823-2828.
24. Law MR. Lowering heart disease risk with cholesterol reduction: evidence from observational studies and clinical trials. Eur Heart J 1999; 1(Suppl S):S3-S8.
25. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995; 92(5):1355-1374.
26. Libby P. Atherosclerosis: the new view. Sci Am. 2002; 286(5):46-55.
27. Fuster V. Elucidation of the role of plaque instability and rupture in acute coronary events. Am. J. Cardiol. 1995; 76(9):24C-33C.
28. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridem-ia as a cardiovascular risk factor. Am J Cardiol. 1998; 81(4A):7B-12B.
29. Avins AL, Neuhaus JM. Do triglycerides provide meaningful information about heart disease risk? Arch Intern Med. 2000; 160(13):1937-1944.
30. Simons LA, Simons J, Friedlander Y, McCallum J. Cholesterol and other lipids predict coronary heart disease and is-chemic stroke in the elderly, but only in those below 70 years. Atherosclerosis. 2001; 159(1):201-208.
31. Sharett AB, Ballantyne CM, Coady SA. Coronary heart disease prediction from lipoprotein cholesterol levels, tri-glycerides, lipoprotein (a), apolipoproteins A-1 and B, and HDL density subfractions. The Atherosclerosis Risk (ARIC) in Communities Study. Circulation 2001; 104:1108-1113.
32. Criqui MH, Heiss G, Cohn R, Cowan LD, Suchindran CM, Bangdiwala S, Kritchevsky S, Jacobs DR, O’Grady HK, Davis CE. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med. 1993; 328(17):1220-1225.
33. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Ware-ham N, Bingham S, Boekholdt SM, Khaw KT, Gudnason V. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007; 115(4):450-458.
34. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, Frick MH. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation. 1992; 85(1):37-45.
35. Havel RJ. Role of triglyceride-rich lipoproteins in progression of atherosclerosis. Circulation. 1990; 81(2):694-696.
36. Grundy SM. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation. 2002; 106(20):2526-2529.
37. Krauss RM. Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol. 1998; 81(4A):13B-17B.
38. Takeichi S, Yukawa N, Nakajima Y, Osawa M, Saito T, Seto Y, Nakano T, Saniabadi AR, Adachi M, Wang T, Nakajima K. Association of plasma triglyceride-rich lipoprotein remnants with coronary atherosclerosis in cases of sudden cardiac death. Atherosclerosis. 1999; 142(2):309-315.
39. Karpe F, Boquist S, Tang R, Bond GM, de Faire U, Hamsten A. Remnant lipoproteins are related to intima-media thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides. J Lipid Res 2001; 42(1):17-21.
40. Abbott RD, Donahue RP, Kannel WB, Wilson PW. The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham Study. JAMA. 1988; 260(23):3456-3460.
41. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989; 79(1):8-15.
42. Wilson PW, Garrison RJ, Castelli WP, Feinleib M, McNamara PM, Kannel WB. Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols. Am J Cardiol. 1980; 46(4):649-654.
43. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis. 1996; 124(Suppl):S11-S20.
44. Libby P, Schoenbeck U, Mach F, Selwyn AP, Ganz P. Cur-rent concepts in cardiovascular pathology: the role of LDL cholesterol in plaque rupture and stabilization. Am J Med. 2002; 104(2A):14S-8S.
45. Stanger O, Fowler B, Piertzik K, Huemer M, Haschke-Becher E, Semmler A, Lorenzl S, Linnebank M. Homocysteine, folate and vitamin B12 in neuropsychiatric diseases: review and treatment recommendations. Expert Rev Neurother. 2009; 9(9):1393-1412.
46. Hoffman M. Hypothesis: hyperhomocysteinemia is an indicator of oxidant stress. Med. Hypotheses. 2011; 77(6):1088-1193.
47. Lok A, Mocking RJ, Assies J, Koeter MW, Bockting CL, deVries GJ, Visser I, Derks EM, Kayser M, Schene AH. The one-carbon-cycle and methylenetetrahydrofolatereductase (MTHFR) C677T polymorphism in recurrent major depres-sive disorder; influence of antidepressant use and depres-sive state? J. Affect. Disord. 2014; 166:115-123.
48. Nabi H, Bochud M, Glaus J, Lasserre AM, Waeber G, Vollenweider P, Preisig M. Association of serum homocysteine with major depressive disorder: results from a large population-based study. Psychoneuroendocrinology. 2013; 38(10):2309-2318.
49. Wang ZM, Zhou B, Nie ZL, Gao W, Wang YS, Zhao H, Zhu J, Yan JJ, Yang ZJ, Wang LS. Folate and risk of coronary heart disease: a meta-analysis of prospective studies. Nutr. Metab. Cardiovasc. Dis. 2012; 22(10):890-899.
50. Humphrey LL, Fu R, Rogers K, Freeman M, Helfand M. Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. Mayo Clin Proc. 2008; 83(11):1203-1212.
51. Ueland PM, Refsum H, Beresford SA, Vollset SE. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr. 2000; 72(2):324-332.
52. Raiko JR, Oikonen M, Wendelin-Saarenhovi M, Siitonen N, Kähönen M, Lehtimäki T, Viikari J, Jula A, Loo BM, Huupponen R, Saarikoski L, Juonala M, Raitakari OT. Plasminogen activator inhibitor-1 associates with cardiovascular risk factors in healthy young adults in the Cardiovascular Risk in Young Finns Study. Atherosclerosis. 2012; 224(1):208-212.
53. Zhuang P, Wo D, Xu ZG, Wei W, Mao HM. Dynamic changes in plasma tissue plasminogen activator, plasminogen activator inhibitor-1 and beta- thromboglobulin content in ischemic stroke. J Clin Neurosci. 2015; 22(7):1123-1127.
54. Tofler GH, Massaro J, O’Donnell CJ, Wilson PW, Vasan RS, Sutherland PA, Meigs JB, Levy D, D’Agostino RB Sr. Plasminogen activator inhibitor and the risk of cardiovascular disease: The Framingham Heart Study. Thrombosis Res. 2016; 140: 30-35.
55. Lominadze D, Dean WL, Tyagi SC, Roberts AM. Mecha-nisms of fibrinogen-induced microvascular dysfunction dur-ing cardiovascular disease. Acta Physiologica (Oxf). 2010; 198(1):1-13.
56. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson JD, Thomp-son SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986; 2(8506):533-537.
57. Lind M, Boman K, Johansson L, Nilsson TK, Järvholm LS, Jansson JH. D-dimer predicts major bleeding, cardiovascular events and all-cause mortality during warfarin treatment. Clin Biochem. 2014; 47(7-8):570-573.
58. Fruchter O, Yigla M, Kramer MR. D-dimer as a prognostic biomarker for mortality in chronic obstructive pulmonary disease exacerbation. Am J. Med. Sci. 2015; 349(1):29-35.
59. Nishida H, Horio T, Suzuki Y, Iwashima Y, Tokudome T, Yoshihara F, Nakamura S, Kawano Y. Interleukin-6 as an independent predictor of future cardiovascular events in high-risk Japanese patients: comparison with C-reactive protein. Cytokine. 2011; 53(3):342-346.
60. Reichert S, Schlitt A, Benten AC, Hofmann B, Schaller HG, Schulz S. The interleukin 6 c.-174 CC genotype is a predic-tor for new cardiovascular events in patients with coronary heart disease within three years follow-up. Cytokine. 2016; 83:136-138.
61. Buraczynska M, Zukowski P, Drop B, Baranowicz-Gaszczyk I, Ksiazek A. Effect of G(-174)C polymorphism in interleukin-6 gene on cardiovascular disease in type 2 diabetes patients. Cytokine. 2016; 79:7-11.